Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 412Carcinoma, Non-Small-Cell Lung 359Neoplasms 327Prostatic Neoplasms 267Colorectal Neoplasms 261Multiple Myeloma 204Lung Neoplasms 195Neoplasm Metastasis 183Leukemia, Myeloid, Acute 158Ovarian Neoplasms 151Pancreatic Neoplasms 143Squamous Cell Carcinoma of Head and Neck 134Melanoma 125Recurrence 99Carcinoma, Renal Cell 99Glioblastoma 96Endometrial Neoplasms 96Stomach Neoplasms 93Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Lymphoma, Non-Hodgkin 92Carcinoma, Hepatocellular 92Head and Neck Neoplasms 91Lymphoma 88Triple Negative Breast Neoplasms 84Uterine Cervical Neoplasms 80Brain Neoplasms 79Sarcoma 78Glioma 75Urinary Bladder Neoplasms 74Lymphoma, Large B-Cell, Diffuse 74

Interventions

thymoglobulin 1luspatercept 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × beta-Thalassemia × 30 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡